环球合伙公司 GLP
$45.01 +$3.34 (+8.02%)
休市 · Nov 7, 9:10 am ET · 最新盘后价 $44.30 -1.58%
开盘$43.98
昨收$41.67
当日区间$41.21 – $45.01
成交量160.2K
市值$1.53B
市盈率（TTM）9.2
股息率6.73%
GLP 相关新闻
匹配 Global Partners 或代码 GLP 的头条新闻，按最新排序。
- Accelerating global expansion! Hengrui Pharma licenses its oral GLP-1/GIP weight-loss drug to Novo-Nordisk A/S, with potential deal value reaching up to $2.6 billion. 中性
- Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Drug
- Will GLP-1s Hurt Food Stocks? Assessing the Changing Consumer.
- Raymond James Initiates Global Partners(GLP.US) With Hold Rating
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/G
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1R
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITY
- Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification. 正面
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OFASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THETREATMENT OF DIABETES
- Jiaze Renewables Corporation: Jiaze New Energy Co., Ltd. Simplified Equity Change Report (Information Discloser: GLP Renewable Energy Investment I Limited)
- Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term Upside
- Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform
- Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology
- Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It's Moving Beyond GLP-1s. -- Barrons.com 正面
- ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATEDPLACEBO-ADJUSTED HBA1C REDUCTION OF 1.7% AT 12 WEEKS FROMITS U.S. PHASE II STUDY IN PARTICIPANTS WITH DIABETES
暂无评论——快来第一个聊聊 GLP。